Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

EORTC hosts joint session with ESTRO to focus on latest developments in soft tissue sarcoma treatment

The EORTC will host a joint session with ESTRO at ESTRO 33 focusing on current developments in soft tissue sarcoma treatment. It will take place from 14:30- 16:00 on Monday, 07 April 2014 in Vienna, Austria and will be co-chaired by Professors Jean-Yves Blay of the Centre Leon Berard in Lyon, France and past EORTC President and Philippe Maingon of the Centre Georges-Fran-ois-Leclerc in Dijon, France, and Chair of the EORTC Radiation Oncology Group.

3 Dec 2013

Alliance HealthCare Services, ONRAD form strategic affiliation to provide quality services to customers

Alliance HealthCare Services, Inc., a leading national provider of radiology and radiation therapy services, and ONRAD, Inc., a full service radiology provider, have agreed to establish a strategic affiliation to develop and support opportunities to further enhance access to the quality services each company provides to its customers.

2 Dec 2013

Sumitomo receives FDA 510(k) clearance for Proton Therapy System

Sumitomo Heavy Industries, Ltd. announced today that it had received US FDA 510(k) clearance of its Proton Therapy System. It is the first 510(k) cleared medical device for Sumitomo. Proton therapy is a form of radiation therapy, which employs proton beams to kill cancer cells with better dose distribution in comparison with conventional x-rays. Currently 12 facilities are operational and several more are under construction in the United States, and the U.S. proton therapy market is expected to expand in the future.

29 Nov 2013

World's first clinical trial to use MLC tracking system to improve prostate cancer radiotherapy treatment

Researchers and clinicians from the University of Sydney and the Northern Sydney Cancer Centre are leading a world first clinical trial using a tracking system to improve prostate cancer radiotherapy treatment.

28 Nov 2013

Biochemist receives grant to identify pathway to regulate DNA damage repair in cancer cells

Chemotherapy and radiation therapy are often used to kill cancer cells by causing irreparable DNA damage. However, some cancer patients resist chemotherapy and radiation due to a highly active DNA damage repair system.

26 Nov 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Radiation therapy now available via latest version of ACR ppropriateness Criteria

New and updated evidence-based guidelines to help health care providers choose the most appropriate medical imaging exam or radiation therapy for a patient's clinical condition are now available via the latest version of the American College of Radiology (ACR) Appropriateness Criteria.

25 Nov 2013

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting in San Francisco.

25 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

UC San Diego study suggests racial inequality leads to higher mortality in cancer patients

Researchers at the University of California, San Diego School of Medicine say metastatic colorectal cancer patients of African-American descent are less likely to be seen by cancer specialists or receive cancer treatments. This difference in treatment explains a large part of the 15 percent higher mortality experienced by African-American patients than non-Hispanic white patients.

20 Nov 2013

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an IMRT-based treatment strategy, according to the new study conducted by a group of researchers from T-bingen and Munich in Germany. The target volume concept seems to correctly cover individual pelvic nodes, which is indicated by the absence of any nodal recurrence within five years of follow-up.

18 Nov 2013

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

16 Nov 2013

Bleach solution could provide new way to treat skin damage

Processes that age and damage skin are impeded by dilute bleach solution, according to a new study by researchers at the Stanford University School of Medicine.

16 Nov 2013

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced results for the third quarter ended September 30, 2013.

6 Nov 2013

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

The prostate gland produces part of the seminal fluid that protects sperm. It is located in front of the rectum and under the bladder, and surrounds the urethra, the tube through which urine flows from the bladder to and out of the penis.

6 Nov 2013

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

The go-to source for excellence in continuing medical education, Physicians' Education Resource®, LLC, will host the 11th Annual School of Breast Oncology November 7-10 at the Emory University Conference Center in Atlanta, GA.

6 Nov 2013

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

The Princess Margaret Cancer Foundation launches an innovative Fall advertising campaign this month which focuses on the extraordinary team of 63 surgeons, all of whom who are integral reasons why the Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world.

5 Nov 2013

RaySearch Laboratories, Hitachi sign long-term distribution agreement

RaySearch Laboratories AB has entered into a long-term distribution agreement with Hitachi Medical Corporation based in Tokyo, Japan. The agreement means that Hitachi will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation® on the Japanese market from April 1, 2014.

4 Nov 2013

Multidisciplinary care critically important for prostate cancer patients

Only half of the men who receive a prostate cancer diagnosis in North Carolina consult with more than one type of physician before deciding on a course of treatment, according to research presented by University of North Carolina researchers at the 2013 American Society for Radiation Oncology annual meeting on Sept. 24.

31 Oct 2013

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue.

25 Oct 2013

Radiation Therapy News and Research

Further Reading

EORTC hosts joint session with ESTRO to focus on latest developments in soft tissue sarcoma treatment

Alliance HealthCare Services, ONRAD form strategic affiliation to provide quality services to customers

Sumitomo receives FDA 510(k) clearance for Proton Therapy System

World's first clinical trial to use MLC tracking system to improve prostate cancer radiotherapy treatment

Biochemist receives grant to identify pathway to regulate DNA damage repair in cancer cells

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Radiation therapy now available via latest version of ACR ppropriateness Criteria

Phase 1/2 clinical trial data for VAL-083 in glioblastoma is presented at 18th Annual SNO meeting

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

UC San Diego study suggests racial inequality leads to higher mortality in cancer patients

Treatment of pelvic nodes can be easily integrated into IMRT-based treatment strategy

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Bleach solution could provide new way to treat skin damage

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Advanced prostate cancer therapies: an interview with Dr. Nancy Dawson, Lombardi Comprehensive Cancer Center

Physicians' Education Resource to host 11th Annual School of Breast Oncology in Atlanta, GA

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

RaySearch Laboratories, Hitachi sign long-term distribution agreement

Multidisciplinary care critically important for prostate cancer patients

Men treated by self-referring urologists more likely to undergo unnecessary IMRT

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News